Initial Drug Listing - BellamiLuxx Cystic Acne Treatment Lotion
- Manufacturer
- BellamiLuxx LLC
- Effective date
- 2025-12-24
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 20:34:12
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Salicylic Acid 2%
OTC - PURPOSE SECTION
Acne treatment
DOSAGE & ADMINISTRATION SECTION
- For the treatment of acne.
- Penetrates pores to eliminate mostacne blemishes, blackheads and whiteheads.
- Helps prevent new acne blemishes, blackheads and whiteheads.
WARNINGS SECTION
For external use only.
OTC - WHEN USING SECTION
skin irritation and dryness is more likely to occur if you use another topical acnemedication at the same time. lf irritation occurs, only use one topical acne medication at a time.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
lf swallowed, get medical help or contact a Poison Control Center rightaway.
INDICATIONS & USAGE SECTION
- Clean the skin thoroughly before applying this product
- Cover the entire affected area with a thin layer one to three times daily
- Because excessive drying of theskin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor
- If bothersome dryness or peeling occurs, reduce application to once a day or every other day.
INACTIVE INGREDIENT SECTION
Aqua (Water), Propylene Glycol,Butylene Glycol, Glycerin, Cetearyl, Alcohol. Dimethicone, lsononyl Isononanoate,Centella Asiatica Leaf Extract, Triethylhexanoin, PEG/PPG-14/7 Dimethyl Ether,Steareth-21, Aminomethyl Propanol,Steareth-2, Polyacrylate-13,
1,2-Hexanediol, Hydroxyacetophe-none, Glyceryl Stearate, PEG-100Stearate,Panthenol,Polyisobutene.Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Madecassoside, Sophora Flavescens Root Extract,Tocopheryl Acetate, Melaleuca Alternifolia (Tea Tree) Leaf Oil, Niacinamide, Allantoin, Trehalose,Centella Asiatica Extract, Polysorbate20, Ophiopogon Japonicus Root Extract, Opuntia Ficus-Indica Stem Extract, Hamamelis Virginiana (WitchHazel) Extract, Xanthan Gum, Tribulus Terrestris Fruit Extract. Hydroxydecyl Ubiquinone. Asiaticoside, Cornus Officinalis Fruit Extract, Disodium EDTA, Caprylyl Glycol, Pentylene Glycol, Pandanus Amaryllifolius Leaf Extract.
OTC - QUESTIONS SECTION
- Email:service@bellamiluxx.com
- Visit:
www.bellamiluxx.com
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Products#
Every source-derived product name is available through these pages.
- BellamiLuxx Cystic Acne Treatment Lotions
- Salicylic Acid 2%
- DIMETHICONE
- POLYISOBUTYLENE (55000 MW)
- STEARETH-2
- .ALPHA.-TOCOPHEROL ACETATE
- HAMAMELIS VIRGINIANA (WITCH HAZEL) LEAF WATER
- OPUNTIA FICUS-INDICA STEM
- PROPYLENE GLYCOL
- BUTYLENE GLYCOL
- STEARETH-21
- PANTHENOL
- EDETATE DISODIUM
- ISONONYL ISONONANOATE
- CENTELLA ASIATICA LEAF WATER
- TRIETHYLHEXANOIN
- GLYCERIN
- 1,2-HEXANEDIOL
- POLYACRYLATE-13
- AQUA
- OPHIOPOGON JAPONICUS ROOT
- AMINOMETHYL PROPANOL
- CAPRYLYL GLYCOL
- HYDROXYACETOPHENONE
- HYDROXYDECYL UBIQUINONE
- POLYSORBATE 20
- XANTHAN GUM
- CORNUS OFFICINALIS FRUIT
- CETEARETH-20
- PEG/PPG-14/7 DIMETHYL ETHER
- PENTYLENE GLYCOL
- TREHALOSE
- ASIATICOSIDE
- PANDANUS AMARYLLIFOLIUS LEAF
- PEG-100 STEARATE
- MADECASSOSIDE
- SOPHORA FLAVESCENS ROOT
- SALICYLIC ACID
- GLYCERYL STEARATE
- ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER (60000 MPA.S)
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 87205-002 | 87205-002-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 46bd65e2-6e8e-e39e-e063-6294a90adcf1 | 469ad2a5-e97f-1820-e063-6294a90a8970 | 2025-12-24 | Warnings | 46bd65e2-6e8e-e39e-e063-6294a90adcf1 469ad2a5-e97f-1820-e063-6294a90a8970 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
